Abstract
The benefit of adjuvant chemotherapy (AdjCT) in all stage II patients (pts) with colon cancer is not clear. Characterization of high-risk subgroups may shed light on this matter. The aim of this study was to determine patterns of AdjCT prescription and its impact on disease-free survival (DFS) in stage II CC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
